![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. The Company has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhe... Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. The Company has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. In addition to advancing both drug candidates in Phase 2 clinical trials, the Company remains active in exploring other advanced drug development opportunities while maintaining its legacy assets, including CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP). Show more
Period โ | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.008 | 0.008 | 0.008 | 56508 | 0.008 | CS |
4 | 0.0048 | 150 | 0.0032 | 0.017 | 0.0032 | 46376 | 0.01232069 | CS |
12 | 0.002 | 33.3333333333 | 0.006 | 0.017 | 0.0011 | 48770 | 0.00736196 | CS |
26 | -0.01 | -55.5555555556 | 0.018 | 0.019 | 0.0011 | 89045 | 0.01195008 | CS |
52 | -0.03675 | -82.1229050279 | 0.04475 | 0.06 | 0.0011 | 138198 | 0.01587788 | CS |
156 | -0.0979 | -92.4457034939 | 0.1059 | 1.09 | 0.0011 | 124817 | 0.11630221 | CS |
260 | -0.182 | -95.7894736842 | 0.19 | 1.09 | 0.0011 | 85621 | 0.11304339 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions